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Abstract
Background: Soft tissue sarcomas comprise less than 1% of all solid malignancies. The presentation and behavior of
these tumors differs depending on location and histological characteristics. Standard therapy consists of complete surgical
resection in combination with adjuvant radiotherapy. The role of chemotherapy is not clearly defined and is largely
restricted to clinical trials. Only a limited number of agents have proved to be effective in soft tissue sarcomas. The use
of doxorubicin, epirubicin and ifosfamide allowed response rates of more than 20%. In addition, recent chemotherapy
trials did not demonstrate any significant differences in efficacy for various histological subtypes.
Methods: The objective of this study was to gain additional information about the chemosensitivity of soft tissue
sarcomas to seven 7 different chemotherapy agents as single drugs and 4 combinations. Therefore we used an established
ATP based in-vitro testing system and examined 50 soft tissue sarcomas. Chemosensitivity was assessed using a luciferin-
luciferase-based luminescence assay providing individual chemosensitivity indices for each agent tested.
Results: The sensitivity varied widely according to the histological subtypes. The tumors state of cellular
dedifferentiation played a crucial role for the efficiency of the chemotherapeutic agents. The sensitivity also depended on
the presentation of the sarcoma as a primary or recurrent tumor. The highest sensitivity was demonstrated for
actinomycin D as a single agent, with 74% of the tumor samples exhibiting a high-grade sensitivity (20% low sensitivity,
no resistance). The combination of actinomycin D and ifosfamide yielded a high sensitivity in 76% (2% resistance).
Doxorubicin as a mono-therapy or in combination with ifosfamide achieved high sensitivity in 70% and 72%, respectively,
and resistance in 6% of the samples.
Conclusion: Chemosensitivity testing is feasible in soft tissue sarcomas. It can be used to create sensitivity and
resistance profiles of established and new cytotoxic agents and their combinations in soft tissue sarcomas. Our data
demonstrate measurable discrepancies of the drug efficiency in soft tissue sarcomas, sarcoma subtypes and tumor
recurrencies. However, current therapeutic regime does not take this in consideration, yet.
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Soft tissue sarcomas account for less than 1% of malig-
nant neoplasms. Approximately 140 different histological
types of sarcomas have been described [1]. Sarcomas arise
in tissues of mesenchymal or ectodermal origin and may
thus occur anywhere in the body The surgical treatment of
choice is the wide surgical excision of the tumor in com-
bination with radiotherapy [2,3]. Currently, about 30–
50% of all patients die within 5 years of primary diagno-
sis. This overall poor prognosis is mainly due to metastatic
disease at the time of diagnosis. Approximately 40% of
patients with high-grade sarcomas develop pulmonary
metastases in spite of local tumor control [4]. The median
duration of survival with apparent metastases is presently
8–12 months [2,4].
Soft tissue sarcomas are notoriously resistant against most
chemotherapeutic agents [5]. As first line treatment, only
doxorubicin (adriamycin), epirubicin and ifosfamide
have achieved a single-agent activity of more than 15%
resulting in response rates of 18%-29% [6,7]. The combi-
nation of anthracyclines and ifosfamide resulted in
response rates of 40%-50%, with 10% of patients in com-
plete remission [8]. ite the reported association between
remission and prolonged survival, an overall superiority
of combination chemotherapy over the administration of
single-agent doxorubicin has not been established yet.
Ifosfamide can play a major role as a second-line treat-
ment with response rates of up to 30%-50% following the
failure of anthracylin [2,7].
Despite the disparate appearance and histology of sarco-
mas, only few drugs and combinations have been used as
treatment regimes [5,9].
Recently, new strategies have been pursued to improve
treatment options for well defined subgroups of sarco-
mas. One example is the successful use of imatinib hydro-
lasis, a specific tyrosine kinase inhibitor, in
gastrointestinal stromal tumors [10,11].
Several new drugs such as exatecan, TZT 1027, trofosfa-
mid and topotecan are under investigation [12-15].
Another promising agent for the treatment of soft tissue
sarcomas is ET-743. Several clinical trials have shown
response rates of up to 20% in untreated and 10% in pre-
treated sarcoma patients. Approximately 50% of patients
in these series have shown long-lasting stabilization of
disease [4,9,16,17].
In the present study we used a testing system, the ATP-
based tumor sensitivity assay (ATP-TCA) (Fig. 1) The suc-
cessful use of ATP-TCA has been demonstrated for pretest-
ing of chemosensitivity in melanoma, breast and ovarian
cancer [18-20] as well as other tumors [21-26]. Based on
these results, we performed in vitro chemosensitivity test-
ing with the ATP-TCA in patients with soft tissue sarcoma.
The aim of this study was to evaluate the feasibility of
ATP-TCA in soft tissue sarcomas and to gain information
about their chemosensitivity profiles with regard to sub-
type, grade of differentiation and tumor recurrence.
Patients and Methods
After informed consent was obtained, the tumors were
resected in 50 patients with diagnosed sarcomas of the
extremities. The group of tumors included liposarcomas
(n = 17), malignant fibrous histiocytomas (MFH/NOS; n
= 16), extraskeletal chondrosarcomas (n = 8), rhabdomy-
osarcomas (n = 5) and malignant peripheral nerve sheet
tumors (MPNST;n = 4). Clinical staging of the patients
was performed in accordance with the criteria of the
American Joint Committee on Cancer. The mean age of
the patients was 63 years, ranging from 32–76 years. The
sex distribution was 20 females and 30 males. The sarco-
mas were primary tumors in 21 patients and recurrencies
in 29 patients. None of the patients had received adjuvant
chemotherapy, neither before nor after surgery. All
patients with recurrent tumors had radiotherapy follow-
ing the excision of the tumor. All patients underwent
wide, complete resection of the tumor. Histological grad-
ing showed GII in 17 tumors and GIII in 33 tumors (Tab.
1).
Tumor tissue was sampled under sterile conditions by a
histopathologist and stored in cell culture medium
(DMEM, Sigma™, Germany) with antibiotics (100 U/ml
penicillin and 100 µg/ml streptomycin) at 4°C. In vitro
chemosensitivity testing was performed with a ATP-based
assay (ATP-TCA, DCS Innovative Diagnostic Systems®,
Hamburg, Germany) [27]. At least 1 cm3 of tumor tissue
was minced and dissociated enzymatically. The single-cell
suspension was depleted of red blood cells and cellular
debris through Ficoll-Hypaque density gradient centrifu-
gation. After assessing the viability of the cells, a cell count
was conducted. The cells were then incubated in polypro-
pylene round-bottom 96-well plates containing 2 × 104
cells per well. Different cytotoxic agents in different con-
centrations were added to the wells, whereas some wells
received no supplements and served as negative controls.
Applied chemotherapeutics were doxorubicin, epirubicin,
ifosfamide, dacarbazine (DTIC), actinomycin D, cisplatin
and vincristine at six different dilutions (6.25–200%) of
the test drug concentrations (TDC) shown in Tab. 2.
While the concentration of a chemotherapeutic agent is
typically measured in plasma or serum with defined pre-
cision, sensitivity, and specificity, it is possible to clini-
cally and analytically validate the data to be used as test
drug concentration in other biological samples or in cell
cultures http://www.aacc.org/divisions/tdm/default.stm.Page 2 of 12
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mined previously (Andreotti et al. 1995) by reference to
known pharmacokinetic and response data. After 7 days
of incubation at 37°C, 5% CO2 and 100% humidity, the
cells were lysed and the ATP content of each well was
measured by a luciferin-luciferase-based luminescence
assay with a Dynatech ML1000 luminometer (Fig. 1).
Individual sensitivity indices for each test drug or drug
combinations were calculated from the obtained data
curves by summing up the percentages of tumor inhibi-
tion for each drug concentration tested (6.25%, 12.5%,
25%, 50%, 100%, 200%) followed by the subtraction of
Principle of chemosensitivity testing using the ATP luminescence method (ATP-TCA)Figure 1
Principle of chemosensitivity testing using the ATP luminescence method (ATP-TCA). TDC, test drug concentration
Table 1: Basic data of patients with soft tissue sarcomas (n = 50)
n age (mean-range) primary tumors recurrent tumors grade G2 grade G3
Liposarcoma 17 61 (32–73) 9 8 6 11
NOS-Sarcoma/MFH 16 64 (42–69) 7 9 7 9
Extraskeletal Chondrosarcoma 8 65 (62–72) 1 7 2 6
Rhabdomyosarcoma 5 68 (64–76) 4 1 1 4
MPNST 4 59 (55–67) 0 4 1 3
Table 2: Cytotoxic drugs used in the ATP-TCA








*TDC, test drug concentrationPage 3 of 12
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tumor cell growth and minimal drug sensitivity, whereas
a sensitivity index of 0 reflects a complete tumor inhibi-
tion and maximal drug sensitivity. Moreover, the chemo-
sensitivity of the test samples was classified according to
the tumor inhibition at different TDC. The chemothera-
peutic single agents and combinations were arranged in
groups starting from high sensitivity, over moderate sensi-
tivity and low sensitivity, to resistant. The grouping was
performed according to the threshold values shown in
Tab. 3.
Statistical analysis
The statistical significance of differences between sub enti-
ties of soft tissue sarcomas, tumor grading and the com-
parison between primary and recurrent tumors was
calculated by the Mann-Whitney-U-test and the Chi
squared test. P < 0.05 was considered statistically
significant.
Results
ATP-TCA testing was done on 53 tumor samples from 53
patients. 50 (94%) of these tumor samples were included
in the study. 3 samples had to be excluded due to bacterial
infection (n = 2) or mycosis (n = 1). The sensitivity pro-
files of the sarcomas exhibited a significant heterogeneity
in response to the array of different cytotoxic agents (Tab.
4)
The strongest chemoresistance was demonstrated for the
single use of dacarbazine with 95% of the samples being
resistant. The application of vincristine and cisplatin
resulted in rates of resistance of 84% and 82%, respec-
tively. The highest response rate was found for actinomy-
cin D, with 74% of the samples showing a high sensitivity
without any resistances. These positive results were fol-
lowed by doxorubicin and ifosfamide with a highly sensi-
tive response in 70% and 64% and rates of resistance in
6% and 12%, respectively. In contrast, epirubicin had a
markedly lower effect on inhibition, with high sensitivity
Table 3: Classification of ATP-TCA chemosensitivity testing results
Tumor growth inhibition at 200% TDC* Tumor growth inhibition at 25% TDC*
High sensitivity >95% >70%
Moderate sensitivity >95% 50–70%
Low sensitivity >95% <50%
<95% >50%
Resistant <95% <50%
*TDC, test drug concentration
Table 4: Chemosensitivity testing in 50 soft tissue sarcoma patients
Cytotoxics Resistant Low Sensitivity Moderate Sensitivity High Sensitivity Mean Sensitivity 
Index*
Actinomycin D 00/50 (00%) 10/50 (20%) 03/50 (06%) 37/50 (74%) 137
Doxorubicin (Adriamycin) 03/50 (06%) 02/50 (04%) 10/50 (20%) 35/50 (70%) 140
Ifosfamide 10/50 (32%) 00/50 (00%) 02/50 (04%) 32/50 (64%) 234
Epirubicin 08/50 (16%) 00/50 (00%) 12/50 (24%) 30/50 (60%) 245
Cisplatin 39/50 (82%) 11/50 (22%) 00/50 (00%) 00/50 (00%) 444
Dacarbazine 45/50 (95%) 05/50 (5%) 00/50 (00%) 00/50 (00%) 532
Vincristine 42/50 (84%) 08/50 (16%) 00/50 (00%) 00/50 (00%) 513
Doxorucicin + Ifosfamide 03/50 (06%) 00/50 (00%) 11/50 (22%) 36/50 (72%) 139
Actinomycin D + Ifosfamide 01/50 (2%) 08/50 (16%) 03/50 (06%) 38/50 (76%) 163
VAC** 03/50 (06%) 05/50 (10%) 07/50 (14%) 35/50 (70%) 218
CYVADIC*** 02/50 (04%) 00/50 (00%) 15/50 (30%) 33/50 (66%) 255
*Data are means from individual chemosensitivity indices for each test drug or drug combination, which were calculated by summing up the tumor 
growth inhibition for each drug concentration tested followed by the subtraction of 600. A sensitivity index of 600 indicates unrestrained tumor cell 
growth and minimal drug sensitivity, whereas a sensitivity index of 0 reflects complete tumor growth inhibition and maximal drug sensitivity.
**VAC: Vincristine, Actinomycin D, Cyclophosphamide
***CYVADIC: Cyclophosphamide, Vincristine, Doxorubicin, DacarbazinePage 4 of 12
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inhibition of the corresponding concentration of the 7
single agent chemotherapeutics is shown in Fig. 2. It
reveals the superior efficiency of actinomycin D, doxoru-
bicin, dacarbazin and ifosfamide, compared to cisplatin,
vincristine and dacarbazin (Fig. 2).
In addition to single drug testing, four different combina-
tions of agents were submitted to ATP-TCA testing. Chem-
osensitivity was less pronounced for CYVADIC
(cyclophosphamide, vincristine, doxorubicin and
dacabazine) with 66% of the samples showing high sensi-
tivity versus 4% of resistant samples. The VAC combina-
tion (vincristine, actinomycin D and cyclophosphamide)
resulted in 70% of high sensitivity and 6% resistance.
Doxorubicin and ifosfamide in combination yielded
highly sensitive responses in 72% and 6% of resistant
cases. The combined use of actinomycin D and ifosfamide
resulted in the overall strongest chemosensitivity of all
combinations used with 76% of high sensitivity and 2%
of resistance (Tab. 4). The tumor inhibition of the tested
chemotherapeutic agent combinations is demonstrated in
correlation to the agent's concentrations in Fig. 4.
The cytotoxic treatment with actinomycin D resulted in
significantly divergent profiles of chemosensitivity
depending on the histological type of soft tissue sarcoma
(Fig. 4). Rhabdomyosarcomas were especially chemore-
sistant against actinomycin D (p < 0.05).
This is in contrast to the response pattern of other types of
sarcomas to this particular chemotherapy. There was no
difference in chemosensitivity between rhabdomyosarco-
mas and other tumor types for the remaining cytotoxic
drugs used.
Complementary, doxorubicin revealed significantly lower
cytotoxic effect on extraskeletal chondrosarcomas com-
Original data curves obtained with ATP-TCA in 50 soft tissue sarcomasFigure 2
Original data curves obtained with ATP-TCA in 50 soft tissue sarcomas. Each plot shows the corresponding test results with 
seven different cytotoxics as single agents.Page 5 of 12
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remaining chemotherapeutic agents showed no difference
in chemosensitivity between extraskeletal chondrosarco-
mas and the other tumor sub entities tested.
There also was a strong statistical correlation between the
histological grading and the chemosensitivity. GIII
tumors (n = 33) demonstrated a significantly higher
chemosensitivity for actinomycin D, doxorubicin and
ifosfamide than GII tumors did (p < 0.05) (n = 17) (Fig.
6).
Similar results were seen when chemosensitivity of pri-
mary tumors was compared to sensitivity of recurrent
tumors. We found the recurrent tumors to be more
chemosensitive to actinomycin D, doxorubicin and ifosfa-
mide than the primary ones (p < 0.05) (Fig. 7).
Discussion
In view of the limited number of effective chemothera-
peutic drugs with response rates of less than 20%, the
need for more detailed information about the tumor spe-
cific chemoresistance seems obvious [4,5,28]. A testing
system would have to produce repeatable and comparable
results of the chemosensitivity of various tumor types.
Chemosensitivity testing with ATP-TCA proved a success
in acquiring resistance profiles for different
chemotherapeutic agents in metastasizing carcinoma of
Effect of Actinomycin D as single agent measured by ATP-TCA in different types of soft tissue sarcomas (Liposarcomas:n = 17, NOS-Sarcomas/MFH:n = 16, Chondrosarcomas:n = 8, Rhabdomyosarcomas:n = 5, MPNST:n = 4) (p < 0.05)Figure 4
Effect of Actinomycin D as single agent measured by ATP-TCA in different types of soft tissue sarcomas (Liposarcomas:n = 17, 
NOS-Sarcomas/MFH:n = 16, Chondrosarcomas:n = 8, Rhabdomyosarcomas:n = 5, MPNST:n = 4) (p < 0.05).Page 6 of 12
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these tumors, the intra- and inter-assay variability was less
than 15%, which demonstrated a high sensitivity and lin-
earity [29]. In the present study, the ATP-TCA test was
practicable in 94% of all cases and thus represented a fea-
sible method in soft tissue sarcomas.
Only a limited number of cytotoxic drugs, such as doxo-
rubicin, epirubicin and ifosfamide, have been reported to
produce response rates of more than 15% in the treatment
of sarcomas, either as single agents or as part of drug com-
binations. There are no clinical trials providing evidence
of prolonged survival rates after either adjuvant or neoad-
juvant chemotherapy [30-32]. Currently, the EORTC is
not conducting any clinical trials on the efficacy of
chemotherapy in soft tissue sarcomas due to the lack of a
prospected benefit. Chemotherapy is presently used in
metastasized disease only which may account for the low
acceptance of this therapeutic option in adult soft tissue
sarcoma [30,33-36].
Further limiting factors regarding the feasibility of large-
scale trials are the low incidence of sarcomas and the enor-
mous heterogeneity of the types of tumors. At the
moment, pathologists know more than 140 entities that
may explain some problems of classification. The applica-
tion of chemotherapy is thus not differentiated according
to the histological type of tumor, yet.
Doxorubicin has been reported to achieve response rates
of 20% to 26% and represents the most effective chemo-
therapeutic agent among the available first line single
drug therapies [37]. In our study, the ATP-TCA testing of
doxorubicin showed that 70% of tumors reacted highly
sensitive. However, among all cytotoxic agents tested,
doxorubicin proved to be only a second rate treatment
regimen. The overall highest sensitivity of all single
therapeutic agents was demonstrated for actinomycin D.
This is in contrast to the poor clinical response rates of
approximately 17% rendered by this drug [15,38]. Espe-
cially actinomycin D is in common use as single agent and
Effect of Doxorubicin (Adriamycin) as single agent measured by ATP-TCA in different types of soft tissue sarcomas (Liposarco-mas:n = 17, NOS-Sarcomas/MFH:n = 16, Chondrosarcomas:n = 8, Rhabdomyosa comas:n = 5, MPNST:n = 4) (p < 0.05)Figure 5
Effect of Doxorubicin (Adriamycin) as single agent measured by ATP-TCA in different types of soft tissue sarcomas (Liposarco-
mas:n = 17, NOS-Sarcomas/MFH:n = 16, Chondrosarcomas:n = 8, Rhabdomyosarcomas:n = 5, MPNST:n = 4) (p < 0.05).Page 7 of 12
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rhabdomyosarcomas in childhood and hyperthermia/iso-
lated limb perfusion [15,39-41].
Ifosfamide serves as a prime drug in first line treatments
under clinical conditions and as a high-dose cytotoxic
agent in second line applications with response rates of
more than 25% [7,42-45]. Yet, the ATP-TCA
chemosensitivity testing found it to be significantly infe-
rior to actinomycin D and doxorubicin.
The ATP-TCA confirmed strong chemoresistance of soft
tissue sarcomas, known from several clinical trials for vin-
cristine, cisplatin and dacarbazine as single agents
[2,32,42].
Similar results were found for combined chemotherapies.
The CYVADIC combination of Gottlieb has been in use
for over a decade [46], however, the ATP-TCA testing
showed significantly higher chemosensitivities with the
combination of actinomycin D and ifosfamide (Fig. 3).
The analysis of respective histological entities showed,
that specific types of tumors respond in different ways.
Rhabdomyosarcomas were significantly more resistant
against actinomycin D than any of the other tumors tested
(Fig. 4). Another example of sub-entity-dependant
resistance was found in the chemosensitivity of extraskel-
etal chondrosarcomas on doxorubicin. The ATP-TCA test-
ing showed a considerable chemoresistance of these
tumors against doxorubicin, when compared to other
types of soft tissue sarcomas (Fig. 5).
Different test results were also found depending on grad-
ing and whether the sarcoma presented as a primary or a
recurrent tumor.
Chemosensitivity profiles of 50 soft tissue sarcomas divided by tumor grade: G2 (n = 17), G3 (n = 33)Figure 6
Chemosensitivity profiles of 50 soft tissue sarcomas divided by tumor grade: G2 (n = 17), G3 (n = 33). Results shown for 
Actinomycin D, Doxorubicin and Ifosfamide (p < 0.05).Page 8 of 12
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ance of primary tumors was considerably higher than the
resistance of recurrent tumors. These results correspond to
the regularly higher differentiation and the lower turn
over time of primary tumors compared to recurrent
tumors. The superior chemosensitivity of recurrent
tumors is in sharp contrast to the worse prognosis of
recurrencies [47-51].
GII tumors (n = 17) exhibited a significantly higher chem-
oresistance when compared to GIII tumors (n = 33) (Fig.
6). This could be due to the higher mitotic activity of
tumor cells in the GIII group. The test results stress the
importance of the state of cellular differentiation as a cru-
cial parameter for the responsiveness of soft tissue sarco-
mas to cytotoxic therapies [32,36].
The results indicate that protocols for chemotherapy
should be designed based on tumor specificity, sub entity
specificity and according to the tumors grading to
improve the response rates of soft tissue sarcomas.
Conclusion
The pre-therapeutic chemosensitivity testing of cytotoxics
with ATP-TCA offers the opportunity of improving the
hitherto moderate success rates of conventional chemo-
therapy in soft tissue sarcomas. Sarcomas usually are of
sufficient size to gain enough tissue for the testing proce-
dure, a problem often encountered with small carcinomas
of the breast. The test poses no risk or disadvantage for the
patient and should be performed in cooperation with the
oncologist.
To create an individualized chemotherapy protocol, eval-
uation of ATP-TCA chemosensitivity testing correlated
with clinical data and in-vitro results are required. Due to
the limited course of time of this study, the results were
not yet associated with data of clinical responses in long-
term follow-up observations. Future trials on any positive
Chemosensitivity profiles of 50 soft tissue sarcomas divided by primary- (n = 21) and recurrent- (n = 29) tumorsFigure 7
Chemosensitivity profiles of 50 soft tissue sarcomas divided by primary- (n = 21) and recurrent- (n = 29) tumors. Results 
shown for Actinomycin D, Doxorubicin and Ifosfamide (p < 0.05).Page 9 of 12
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testing method.
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